

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONVENIENCE TRANSLATION INTO ENGLISH OF
CONSOLIDATED FINANCIAL STATEMENTS
AT 31 MARCH 2016**

(ORIGINALLY ISSUED IN TURKISH)

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2016**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

	31 March 2016 USD (*)	31 March 2016 TL	31 December 2015 TL
ASSETS			
Current Assets	362.807	1.027.976	1.075.543
Cash and cash equivalents	124.162	351.800	342.810
Trade receivable			
- Other trade receivables	97.890	277.361	275.326
- Due from related parties	58.020	164.393	192.501
Other receivables			
- Due from related parties	-	-	11.089
- Other receivables	153	433	257
Inventories	55.826	158.179	185.074
Prepaid expenses	6.908	19.573	10.482
Derivatives	2.364	6.699	7.189
Other current assets	17.484	49.538	50.815
Non-current Assets	414.564	1.174.626	1.178.532
Other receivables			
- Due from related parties	29.897	84.710	79.456
Joint ventures accounted for by the equity method	79.733	225.915	243.337
Investment property	16.977	48.102	48.418
Property, plant and equipment	255.896	725.059	718.574
Intangible assets	26.701	75.656	76.967
Goodwill	2.114	5.989	5.989
Prepaid expenses	3.150	8.924	5.256
Derivative financial instruments	96	271	535
TOTAL ASSETS	777.371	2.202.602	2.254.075

(*) US Dollar (“USD”) amounts presented above have been translated from Turkish Lira (“TL”) for convenience purposes only, at the official TL bid rate announced by the Central Bank of the Republic of Turkey (“CBRT”) at 31 March 2016, and therefore do not form part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2016**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

	31 March 2016 USD (*)	31 March 2016 TL	31 December 2015 TL
LIABILITIES			
Current liabilities	247.662	701.725	751.107
Short-term financial liabilities	102.177	289.508	337.407
Short-term portion of long-term financial liabilities	25.370	71.882	70.886
Trade payables			
- Other trade payables	101.467	287.500	277.895
- Due to related parties	9.567	27.106	27.510
Other payables			
- Other payables	189	535	508
Unearned revenue	1.612	4.568	7.108
Payables due for employee benefits	944	2.676	2.243
Taxes on income	4.302	12.190	14.544
Provisions	1.972	5.585	13.006
Derivative financial instruments	62	175	-
Non-current Liabilities	82.065	232.524	254.372
Financial liabilities	68.685	194.614	212.946
Trade payables			
- Due to related parties	3.351	9.494	13.974
Derivative financial instruments	186	526	-
Provision for employment termination benefits	7.534	21.348	20.226
Deferred income tax liabilities	2.309	6.542	7.226
Total Liabilities	329.727	934.249	1.005.479
EQUITY	447.644	1.268.353	1.248.596
Attributable to Equity Holders of the Parent	447.634	1.268.325	1.248.548
Share capital	65.293	185.000	185.000
Adjustment to share capital	68.884	195.175	195.175
Share premium	16	44	44
Restricted reserves	37.941	107.501	107.501
Currency translation differences	39.392	111.613	120.438
Hedge funds	(198)	(561)	330
Actuarial gain/loss	(1.833)	(5.194)	(5.194)
Retained earnings	227.730	645.254	445.779
Net income for the year	10.409	29.493	199.475
Non-controlling Interests	10	28	48
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	777.371	2.202.602	2.254.075

(*) USD amounts presented above have been translated from Turkish Lira (“TL”) for convenience purposes only, at the official TL bid rate announced by the CBRT at 31 March 2015, and therefore do not form part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2016**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

	Notes	2016 USD (*)	2016 TL	2015 TL
Continuing operations				
Sales		150.550	442.754	490.021
Cost of sales (-)		(122.433)	(360.063)	(417.793)
Gross profit		28.118	82.691	72.228
Marketing, selling and distribution expenses (-)		(3.809)	(11.202)	(11.590)
General administrative expenses (-)		(4.294)	(12.627)	(9.997)
Research and development expenses (-)		(467)	(1.372)	(1.054)
Other operating income		7.003	20.595	62.005
Other operating expenses (-)		(7.956)	(23.399)	(42.666)
Operating profit		18.595	54.686	68.926
Share of profit/loss of investment in Joint Venture		(3.254)	(9.570)	(11.024)
Financial income		13.802	40.591	54.781
Financial expenses (-)		(14.961)	(43.998)	(51.348)
Profit before tax		14.182	41.709	61.335
Taxation expense on income:				
- Income tax expense		(4.326)	(12.722)	(11.184)
- Deferred tax benefit/(charge)		165	486	(295)
Net income for the year		10.022	29.473	49.856
Other comprehensive income/(expense):				
Changes in fair value of derivative financial instruments		(379)	(1.114)	(140)
Currency translation differences		(3.001)	(8.825)	28.604
Tax effect of comprehensive income		76	223	28
Total comprehensive income		6.718	19.757	78.348
Net income for the period attributable to:				
Equity holders of the parent		10.029	29.493	49.862
Non-controlling interests		(7)	(20)	(6)
		10.022	29.473	49.856
Total comprehensive income attributable to:				
Equity holders of the parent		6.725	19.777	78.354
Non-controlling interests		(7)	(20)	(6)
		6.718	19.757	78.348
Earnings per share for equity holders of the parent (Kr)		0,05	0,16	0,27

(*) USD amounts presented above have been translated from TL for convenience purposes only, at the USD average CBRT bid rates for the period ended 31 March 2016, and therefore do not form part of these consolidated financial statements.